Dr. Mahmoud Abdelaal
Connect on LinkedIn

Abu Dhabi, United Arab Emirates · Open to Medical Affairs Manager roles and above

, Medical Affairs Manager, Rare Disease, Orphan Drugs and Gene Therapy

Medical Affairs Manager, Rare Disease, Orphan Drugs and Gene Therapy

Physician and medical affairs manager in rare disease, orphan drugs and gene therapy across the Gulf, with three launches, a national first in Oman, and work rights in France and Italy.

Connect on LinkedInSee the launch record
100+
KOL network across the Gulf
20+
orphan and speciality products
6
GCC markets covered
3
therapy launches led
6
medical affairs staff managed
118
compliance modules completed
Dr. Mahmoud Abdelaal, medical affairs manager in rare disease
Published as Mahmoud Abdelaal, and on one 2016 paper as Mahmoud ZakyMBBCh, PGD

In short

Dr. Mahmoud Abdelaal is a physician and medical affairs manager based in Abu Dhabi, United Arab Emirates. He has led medical affairs for rare disease, orphan drug and gene therapy portfolios across six Gulf markets, managed a team of six, launched three therapies and completed 118 modules of research ethics and good clinical practice training.

Rare diseaseOrphan drugsHaematologySickle cell diseaseAcute hepatic porphyriaCystic fibrosisGene therapyRNAi therapeuticsNeuromuscular disordersDuchenne muscular dystrophyNephrologyIgA nephropathyOncologyImmunologyRespiratoryMetabolic diseaseCongenital leptin deficiencyNeonatologyTransplant immunosuppressionDermatology

Open to

Medical Affairs Manager and above, including Associate Director, Medical Director, Senior MSL and Medical Advisor roles.

Based in Abu Dhabi, United Arab Emirates. Open to roles in the Gulf, in Italy and in France.

Current clinical post: medical interpreter and patient communication specialist at Cleveland Clinic Abu Dhabi, held alongside the medical affairs career.

Abstract illustration of the six Gulf markets covered

Work rights

Egyptian national, resident in the United Arab Emirates, with residency and work rights in France and Italy.

Languages

  • ArabicNative

    Including Gulf dialects

  • EnglishFull professional, C1

    IELTS 7.5, TOEFL 91

  • ItalianElementary, A1

    Intensive courses in progress

  • GermanBasic

In numbers

Abstract illustration of evidence and data review
6

Gulf markets covered

United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Bahrain and Oman.

24

orphan and speciality products

Partner portfolios carried across six therapy areas.

18

partner companies represented

Including Alnylam, Vertex, Bluebirdbio, PTC, Incyte and Calliditas.

100+

KOL network across the Gulf and MENA

Built over years of field medical work; still active.

34

KOLs at the Myalept launch conference

Funded through non-pharmaceutical sponsors.

3

congenital leptin deficiency patients on treatment

Within three months of launch, in an ultra-rare condition.

60+

physicians trained on clinical data and mechanism of action

Advisory boards, workshops and hospital visits across the Gulf.

30+

physicians trained on acute hepatic porphyria

Part of the Oman programme.

6

months to national approval in Oman

Following the country's first official acute hepatic porphyria diagnosis.

300+

cystic fibrosis patients in treatment within a year

Government coverage secured for eligible patients.

6

medical affairs staff managed

Plus 10+ sales and medical representatives and product specialists trained.

118

compliance and ethics modules completed

Across the CITI Program, with credential IDs recorded.

Launches

Five programmes, and what each one changed.

Congenital leptin deficiency illustration
Pre-launch, launch and post-launchGulf Cooperation Council

Myalept

Congenital leptin deficiency

Held the medical plan from pre-launch through launch and post-launch, as the medical counterpart to the regional distribution partners.

  • Medical launch plan prepared and executed across the Gulf
  • Launch conference funded through sponsors and attended by 34 key opinion leaders
  • Three patients on treatment within three months of launch
  • KOL mapping for a condition with very few diagnosed patients in the region
Acute hepatic porphyria illustration
Market assessment and pre-launchOman, then the wider Gulf

Givosiran

Acute hepatic porphyria

Ran the market assessment and pre-launch work in Oman, where the country's first official diagnosis followed, and national approval came through within six months.

  • Secured the first official diagnosis of acute hepatic porphyria in Oman
  • National approval achieved within six months of the assessment
  • Jointly managed the Porphyria Ambassador awareness programme
  • 30 or more physicians trained on the condition
Cystic fibrosis illustration
All phasesGulf Cooperation Council

Ivacaftor and the cystic fibrosis portfolio

Cystic fibrosis

Held the medical work across the cystic fibrosis portfolio from assessment through launch and post-launch.

  • 300 or more patients in treatment within twelve months
  • Government coverage secured for the patient population
  • Advisory boards and specialist education across the Gulf centres
Sickle cell disease illustration
All phasesGulf Cooperation Council

Endari

Sickle cell disease

Led the sickle cell disease programme, including a Gulf real-world evaluation during the COVID-19 period.

  • First-author abstract in Blood, the journal of the American Society of Hematology, 2020
  • Reported a 63 per cent lower occurrence of acute chest syndrome, attributed in the abstract to additional analysis of the phase 3 programme
  • Also published in the HemaSphere abstracts book and the Journal of Sickle Cell Disease and Hemoglobinopathies
  • The work was used in investor and partner discussions for the programme
Duchenne muscular dystrophy illustration
Market assessmentGulf Cooperation Council

Translarna

Duchenne muscular dystrophy

Assessed the Gulf market and the patient pathway for a rare neuromuscular therapy.

  • Patient pathway and diagnosis mapping across the Gulf
  • Input to the medical strategy for a therapy with a narrow eligible population

Portfolio

Eighteen partner companies and twenty four products across six therapy areas.

MAmarket assessmentPLpre-launchLAlaunchPoLApost-launch

Haematology and genetic disorders

  • Bluebirdbio

    Lentiglobin

    Gene therapy for sickle cell disease

    MA

  • Global Blood Therapeutics

    Oxbryta

    Small molecule therapy for sickle cell disease

    MAPL

  • Emmaus Medical

    Endari (L-glutamine)

    Amino acid therapy for sickle cell disease

    MAPLLAPoLA

  • Orchard Therapeutics

    Trimvelis, OTL-200

    Ex vivo gene therapy for ADA-SCID and metachromatic leukodystrophy

    MA

  • Mirum Pharmaceuticals

    Cholbam

    Bile acid replacement for bile acid synthesis disorders

    PoLA

Metabolic and neuromuscular

  • Alnylam

    Givosiran, Patisiran, Lumasiran

    RNAi therapies for acute hepatic porphyria, hATTR amyloidosis and primary hyperoxaluria type 1

    MAPL

  • PTC Therapeutics

    Translarna, Waylivra, Evrysdi

    Duchenne muscular dystrophy, familial chylomicronaemia syndrome, spinal muscular atrophy

    MA

  • Green Cross

    Hunterase

    Enzyme replacement for Hunter syndrome

    PoLA

  • Lucane Pharma

    Ucedane

    Nitrogen scavenger for urea cycle disorders

    PoLA

  • Mitsubishi Tanabe

    Radicava

    Free radical scavenger for amyotrophic lateral sclerosis

    MA

  • Etoro Pharma

    Keveyis

    Carbonic anhydrase inhibitor for primary periodic paralysis

    MA

Nephrology and immunology

  • Calliditas Therapeutics

    Nefecon

    Targeted-release budesonide for IgA nephropathy

    MAPL

  • Aegerion

    Myalept

    Leptin analogue for congenital leptin deficiency

    PLLAPoLA

  • Veloxis

    Envarsus XR

    Tacrolimus immunosuppressant for transplant patients

    MA

Oncology

  • BeiGene

    Zanubrutinib

    BTK inhibitor for CLL, SLL and Waldenstrom macroglobulinaemia

    MA

  • Incyte

    Ruxolitinib, Pemigatinib, Tafasitamab

    Polycythaemia vera, cholangiocarcinoma and diffuse large B-cell lymphoma

    MA

Respiratory

  • Vertex Pharmaceuticals

    Ivacaftor, Lumacaftor, Tezacaftor, Trikafta

    CFTR modulators for cystic fibrosis

    MAPLLAPoLA

Neonatology

  • BCO Pharma

    Special Formula

    Therapy for hypotension in neonates

    MA
Abstract illustration of a product portfolio

Experience

Medical affairs experience

Dec 2018 to Dec 2020

Regional Medical Affairs Manager, GCC (Rare Diseases)

Taiba Pharma LLC

Muscat, Oman

Manager level

Rare diseaseOrphan drugsTeam of sixGovernanceLaunch
  • Held medical affairs for a Gulf portfolio of more than 20 orphan and speciality products, including the former Aegerion range, as the standing medical counterpart to the regional distribution partners.
  • Managed six medical affairs staff and trained more than 60 physicians on clinical data and mechanisms of action, 30 or more of them on acute hepatic porphyria.
  • Took Myalept from pre-launch through launch and post-launch across the Gulf, including a sponsor-funded launch conference for 34 key opinion leaders.
  • Built and maintained a network of more than 100 key opinion leaders across the region, and passed treatment pattern and competitor insight back to medical strategy.
  • Wrote and instituted the governance framework for partner engagements, covering medical education, research participation and travel sponsorship, against FDA, EMA and Gulf requirements.
  • Ran regional advisory boards, symposia and expert input meetings, and trained sales and medical representatives and product specialists.
  • Reviewed promotional, educational and scientific material for accuracy and balance and supported medical information and pharmacovigilance activity.
  • Worked across the six Gulf markets with commercial, regulatory and access colleagues on medical input to business development decisions.

Jan 2021 to Dec 2025

Co-founder and Medical and Scientific Advisor (Contract)

Cyntexia Pharma

Abu Dhabi, United Arab Emirates

Fixed-term engagement

Regulatory firstMarket assessmentAdvisoryProduct built
  • Led the regulatory pathway that made this the first officially registered cannabidiol product in the Gulf, in a region where the category is restricted.
  • Advised pharmaceutical clients on rare disease medical affairs across the Gulf, including evidence planning, scientific communications and compliant field engagement.
  • Ran market surveys and patient cluster analysis for IQVIA, subcontracted by Global Blood Therapeutics, mapping diagnosis gaps in sickle cell disease.
  • Supported a USD 3 million seed raise for Gulf market entry by preparing clinical and value material for investor discussions.
  • Designed and built Spectria, a platform that measures and improves professional communication, built first for medical affairs training.

Nov 2016 to Nov 2018

Medical Science Liaison, Dermatology

Local pharmaceutical company, Egypt

Cairo, Egypt

Full time

MSLDermatologyField medical
  • Presented clinical trial data for dermatology therapies to specialists across Egypt and handled unsolicited medical enquiries from healthcare professionals.
  • Built relationships with key opinion leaders across Egypt and passed field insight on treatment patterns and competitor activity to the medical strategy team.
  • Supported clinical studies at site, including site initiation, patient recruitment and data monitoring under good clinical practice.

Clinical and research experience

Oct 2023 to Present

Clinical Medical Interpreter and Patient Communication Specialist

Cleveland Clinic Abu Dhabi

Abu Dhabi, United Arab Emirates

Current clinical post, held alongside the medical affairs career

  • Carry clinical conversations between English speaking specialists and Arabic speaking patients in neurology and oncology, including consent, prognosis and treatment expectations.
  • Keep a standing scientific exchange with senior UAE specialists inside the hospital system where rare disease patients are treated.

May 2014 to Oct 2015

Clinical Research Fellow (SALSA, iCAMP and Bio5 Labs)

University of Arizona

Tucson, Arizona, United States

Fellowship

  • Directed a clinical study with the Southern Arizona Limb Salvage Alliance on wound healing and frailty in patients with diabetes, and wrote the institutional review board protocols.
  • Worked with research devices including gait and balance analysis systems, pressure mapping, activity monitors and hyperspectral imaging for tissue oxygen measurement.
  • Published in Clinical Biomechanics in 2016 and co-authored a Springer chapter in 2015, and presented at five international conferences including the International Symposium on the Diabetic Foot and the American Podiatric Medical Association meeting.
  • Analysed clinical data in SPSS and Stata.

Jan 2016 to Jul 2016

General Physician

Ministry of Health

Beni Suef, Egypt

Full time

  • Provided non-surgical care in a public hospital, including assessment, diagnosis, treatment plans and patient education across a broad caseload.

Mar 2013 to Mar 2014

Clinical Medical Intern (Rotating)

Benha University

Benha, Egypt

Internship, including three months at Sheikh Khalifa Medical City, managed by Cleveland Clinic

  • Rotated through internal medicine, surgery, paediatrics, obstetrics and gynaecology, and emergency medicine.
Abstract illustration of an advisory board meeting

Scientific exchange

Advisory boards, symposia and expert input meetings built and run across the Gulf, with the clinical input fed back into the medical plan.

100+

specialists in the regional network

34

KOLs at one launch conference

6

markets held under one medical plan

  • Built and ran regional advisory boards, symposia and expert input meetings, including a launch conference attended by 34 key opinion leaders.
  • Secured the funding for that conference through non-pharmaceutical sponsors, keeping the meeting compliant and outside promotional rules.
  • Held the regional medical plan across six markets and coordinated country teams and partner teams through their own management lines.
  • Scientific exchange with specialists on mechanism of action, clinical data and the patient pathway, in the language and depth each audience needed.
  • Escalated medical enquiries closed out with documented, quality-checked responses, alongside pharmacovigilance support.

Capability building

  • Managed six medical affairs staff during the Taiba Pharma period, December 2018 to December 2020, as Regional Medical Affairs Manager for the Gulf.
  • Trained 10+ sales and medical representatives and product specialists, and 60+ physicians on clinical data and mechanisms of action.
  • Trained 30+ physicians specifically on acute hepatic porphyria, working alongside the Oman launch programme.
  • Built training content from the clinical evidence rather than the promotional summary, so the science survived the questions it was going to get.
  • Completed 118 compliance, ethics and good clinical practice modules across the CITI Program and Coursera, all listed with their credential IDs.
Abstract illustration of a training session

What I do

01

Medical affairs

  • Medical strategy and therapy area planning across six markets
  • Scientific exchange with specialists, advisory boards and expert input meetings
  • Key opinion leader engagement and network building
  • Medical review of promotional, educational and scientific material
  • Medical information and pharmacovigilance support
  • Congress and symposium medical activity
02

Evidence and research

  • Real world evidence planning and delivery
  • Investigator initiated study support under FDA regulations and good clinical practice
  • Protocol and study design for safety, tolerability and efficacy
  • Patient registries and long term outcome tracking
  • Publication and abstract writing, first author on two papers
  • Clinical data analysis in SPSS and Stata, and machine learning for evidence work
03

Launch and access

  • Pre-launch, launch and post-launch medical planning
  • Market and diagnosis gap assessment, including patient cluster analysis
  • Government coverage and access support
  • Lifecycle and post-marketing phase four studies
  • Market access and payer conversations with medical evidence
04

Governance and compliance

  • Good clinical practice, ICH E6 against US FDA regulations
  • Informed consent, adverse event detection and serious adverse event reporting
  • Sponsor monitoring, audits and inspections
  • Research ethics review, institutional review boards and human subjects protection
  • Health information privacy and security
  • Conflict of interest disclosure and management, partner engagement governance
05

Leadership

  • Six medical affairs staff managed, plus representatives and product specialists trained
  • More than 60 physicians trained on clinical data
  • Cross functional work with commercial, regulatory, access and R and D colleagues
  • Partner and distributor governance across the Gulf
  • Advisory platform built for training professionals in scientific communication

Therapy areas

Rare diseaseOrphan drugsHaematologySickle cell diseaseAcute hepatic porphyriaCystic fibrosisGene therapyRNAi therapeuticsNeuromuscular disordersDuchenne muscular dystrophyNephrologyIgA nephropathyOncologyImmunologyRespiratoryMetabolic diseaseCongenital leptin deficiencyNeonatologyTransplant immunosuppressionDermatology
Abstract illustration of clinical evidence

Governance

Abstract illustration of document review
  • Medical review of promotional, educational and scientific material for accuracy and balance, across partner portfolios in six markets.
  • Wrote and instituted a governance framework for partner engagements covering medical education, research participation and travel sponsorship.
  • Aligned that framework to FDA, EMA and Gulf regulatory requirements, alongside local and international codes of practice and company SOPs.
  • Medical information and pharmacovigilance support, including escalated medical enquiries closed out with documented, quality-checked responses.
  • Investor-facing clinical and value material prepared for an orphan asset, kept inside the boundaries of non-promotional scientific exchange.
  • Pharmacovigilance training to version 25, with conflict of interest, human research protections and health information privacy training on top.

Toolkit

  • Artificial Intelligence for Scientific Research specialisation, LearnQuest 2022, with a capstone on advanced AI for drug discovery.
  • Statistical analysis in SPSS and Stata for clinical data, from the University of Arizona research period.
  • MIT 6.00x Introduction to Computer Science and Programming.
  • Built a tender-tracking system and a clinical nutrition calculator.
  • Medical and scientific illustration, including the mRNA vaccine infographic drawn for the profile's featured section.
  • AI tooling in daily use for research, drafting and content, disclosed wherever a platform requires it.
Abstract illustration of a connected data model

Evidence

First author2020

Actions of L-Glutamine vs. COVID-19 Suggest Additional Benefit in Sickle Cell Disease

Abdelaal MAZ, Abdelrahman D, Cengiz M, Yavuzer H, Yavuzer S, Bien I, Bhuva P, Pham JV, Siu R, Tang M, Ward A, Goodrow J, Ludlum P, Stark CW, Perrine SP

Blood, the American Society of Hematology, volume 136, supplement 1, pages 11 to 12

Also published in the HemaSphere abstracts book for the 15th Annual Sickle Cell and Thalassaemia Conference and the 1st European Hematology Association Sickle Cell Conference, and in the Journal of Sickle Cell Disease and Hemoglobinopathies, volume VII.

doi.org/10.1182/blood-2020-135903
First author2015

Tissue Repair and Wound Healing: A Trip Back to the Future

Abdelaal MAZ, Giovinco NA, Slepian MJ, Armstrong DG

In Technological Advances in Surgery, Trauma and Critical Care, Springer, New York, pages 563 to 571

doi.org/10.1007/978-1-4939-2671-8_46
Contributing author2016

Gait and balance assessments as early indicators of frailty in patients with known peripheral artery disease

Thiede R, Toosizadeh N, Mills JL, Zaky M, Mohler J, Najafi B

Clinical Biomechanics, volume 32, pages 1 to 7

Published under the name Mahmoud Zaky, fourth in the author list.

doi.org/10.1016/j.clinbiomech.2015.12.002
Presentation2015

The Association Between Frailty and Wound Size, Depression and Pain: A Pilot Study

Abdelaal MAZ, Armstrong DG, Najafi B

7th International Symposium on the Diabetic Foot, The Hague, Netherlands

Poster2015

Frailty Impact on Wound Healing Outcomes Among Diabetic Patients: A Pilot Study

Abdelaal MAZ, Toosizadeh N, Armstrong DG, Mills JL, Najafi B

American Podiatric Medical Association Annual Scientific Meeting, Orlando, Florida

Research ethics and clinical practice training

Nine CITI Program courses, 118 modules in total, completed in June 2014 under his University of Arizona affiliation. Passing score 80 per cent on each course.

Abstract illustration of the research evidence record

Congresses

Five international meetings from the research period, on frailty, wound healing and the diabetic foot.

Abstract illustration of a congress stage
  1. 2015Frailty impact on wound healing outcomes among diabetic patients: a pilot studyAmerican Podiatric Medical Association Annual Scientific Meeting, Orlando
  2. 2015Depression influence on wound size: a pilot studyKISCOMS 5th International Conference of Medical Sciences, Pristina
  3. 2015Pilot study: frailty impact on wound healing, depression and pain7th International Symposium on the Diabetic Foot, The Hague
  4. 2015Pilot study: frailty syndrome impact on wound healingDiabetic Foot Conference, Los Angeles
  5. 2014The association between frailty and wound size, disability and pain: a pilot studyQatar Foundation Annual Research Conference, Doha

Credentials

19 credentials, listed with the identifier an employer or agency can check.

Abstract illustration of verified credentials

Research ethics, GCP and human subjects protection

CITI Program, June 2014, 118 modules in total

  • Conflict of Interest

    CITI Program · June 2014 · scored 88%

    13123744

  • Health Information Privacy and Security (HIPS)

    CITI Program · June 2014 · scored 89%

    13123743

  • GCP for Clinical Trials with Investigational Drugs and Medical Devices (FDA)

    CITI Program · June 2014 · scored 95%

    13123742

  • Biomedical Responsible Conduct of Research

    CITI Program · June 2014 · scored 82%

    13123741

  • Working with the IACUC: Investigators, Staff and Students

    CITI Program · June 2014 · scored 92%

    13123740

  • Native American Research

    CITI Program · June 2014 · scored 100%

    13123739

  • IRB Members

    CITI Program · June 2014 · scored 86%

    13123738

  • Social and Behavioral Research Investigators

    CITI Program · June 2014 · scored 91%

    13123737

  • Biomedical Research Investigators

    CITI Program · June 2014 · scored 100%

    13123736

Drug development and commercialisation

University of California San Diego, Skaggs School of Pharmacy, 2021 to 2022

  • Drug Discovery

    University of California San Diego · December 2021

    S2FT3U66B5ZR

  • Drug Development

    University of California San Diego · December 2021

    VX5SEPFLQCBR

  • Drug Development Product Management Specialization

    University of California San Diego · January 2022

    RV4X8GQB433G

  • Drug Commercialization

    University of California San Diego · January 2022

    GEAJLX2W8U68

Data science and artificial intelligence

LearnQuest, 2022, four courses completed

  • Introduction to Data Science and scikit-learn in Python

    LearnQuest · January 2022

    S2E9N9XWXQJT

  • Machine Learning Models in Science

    LearnQuest · January 2022

    J2XK35D3X78Q

  • Neural Networks and Random Forests

    LearnQuest · January 2022

    FLDFCTPMDK6L

  • Capstone Project: Advanced AI for Drug Discovery

    LearnQuest · January 2022

    XEAJA4PL2XE6

  • AI for Scientific Research Specialization

    LearnQuest · January 2022

    W6A74NALYJPU

Degree

  • Bachelor of Medicine, Bachelor of Surgery (MBBCh)

    Faculty of Medicine, Benha University · December 2012

    254781/2014-03-13

Also recorded

  • Protecting Human Research ParticipantsNational Institutes of Health · 2013
  • Quantitative Methods in Clinical and Public Health Research (PH207x)Harvard School of Public Health · 2013
  • Basic Life Support and First AidBenha University · 2012
  • Pharmacovigilance training, version 25issuer not recorded
  • AACE continuing medical education, 16 credit hoursAACE, with Taiba Pharma

Recognition

Awards and appreciation

Abstract illustration of an award

  • AHSANT badge, volunteer of the month

    Cleveland Clinic, Sheikh Khalifa Medical City · 2009

  • Certificate of Appreciation

    Abu Dhabi Blood Bank and Cleveland Clinic, Sheikh Khalifa Medical City · 2009 to 2014

  • Certificate of Appreciation

    Center of Diabetes and Endocrinology, Abu Dhabi · 2011

  • Certificate of Appreciation, International Volunteer Day

    Cleveland Clinic, Sheikh Khalifa Medical City · 2011

  • Certificate of Appreciation, The Future of Medical Graduates conference

    Benha Faculty of Medicine, Benha University · 2012

  • Certificate of Appreciation, Red Cross blood drive

    University of Arizona, Faculty of Medicine · 2014 and 2015

  • Certificate of Appreciation, volunteers services office

    Cleveland Clinic, Sheikh Khalifa Medical City · 2009

  • Volunteer recognition

    SKMC and American Red Cross Southern Arizona Chapter, blood donor · 2005 to 2015

Volunteering

Abstract illustration of community and donation work

  • Blood donation campaign

    Medical advisor and donor recruiter for a community blood drive

  • Ramadan patient activities

    Coordinated care activities for patients during Ramadan

  • International Volunteering Day

    Organised healthcare workshops and free consultations

  • World Diabetes Day

    Led education sessions on diabetes prevention and management

  • Relief campaign

    Supported medical aid collection and distribution for disaster affected areas

Devices used in clinical research

Abstract illustration of a clinical research device
  • LEGsys gait analysis system
  • BalanSens balance analysis system
  • PAMsys physical activity monitor
  • F-scan pressure mapping system
  • Zephyr BioPatch physiological monitor
  • KENT hyperspectral imaging device
  • SPY laser and dye imaging for blood flow
  • SEM Scanner for early pressure ulcer detection

Memberships

Ten organisations, several held for more than fifteen years.

  • Cleveland Clinic Abu Dhabi volunteers

    Member since 2008

  • Benha students' scientific society

    Member since 2010

  • American Red Cross, Southern Arizona

    Blood donor, 2014 to 2015

  • Abu Dhabi Government Takatof volunteers

    Member, 2007 to 2009

  • Egyptian Medical Student Association

    Member, 2008 to 2009

  • Charity Pharmacy Student Group

    Member, 2008 to 2011

  • Quality assurance programme, student member

    2009 to 2010

  • Ro'ya and Future Hope student groups

    Member, 2007 to 2011

  • Benha Faculty of Medicine student union

    Member, 2010 to 2011

  • Sohag Faculty of Medicine student union

    Member, 2005 to 2006

Abstract illustration of community support

Selected work

Two products I built and three competition entries, all public.

  • The SPECTRIA product page

    Founder and developer

    SPECTRIA

    A measurement instrument for how a person comes across. A recording is scored across five dimensions and benchmarked against the strongest communicator on the team, so delivery becomes something you can see and work on.

    5

    dimensions measured

    Open
  • The Parlo Italiano course homepage

    Founder and developer

    Parlo Italiano

    An Arabic first Italian course. Nineteen lessons from the alphabet to directions, three dimensional arcade games to drill the grammar, and a passport that collects a stamp at each milestone.

    19

    lessons, with 3D practice games

    Open
  • Abstract illustration of a screening report read as a document

    Kaggle, SPR 2026

    Mammography report classification

    Predicting BI-RADS categories from Portuguese mammography reports. Duplicate reports are grouped so they cannot leak across folds, per class thresholds are tuned rather than left at the default, and a TF-IDF and LightGBM baseline is ensembled with transformer models.

    14th

    of 371 teams, private leaderboard, top 4%

    Open
  • Abstract illustration of two layers of cards with threads between them

    Kaggle, NCEMS

    Harmonizing the Data of your Data

    Extracting SDRF sample annotations from proteomics papers. The first pass reads the whole paper with the methods sections prioritised; the second pass checks every extracted value back against the source text, which is what stops the first pass inventing things.

    2

    passes, extraction then verification

    Open
  • Abstract illustration of a cell cluster with one cell highlighted

    Kaggle, Myllia

    Echoes of Silenced Genes

    Predicting how human cancer cells answer CRISPR interference across 5,127 genes, learned from only 80 known perturbations. Six weeks and twenty four notebooks, most of them ruling a hypothesis out.

    7th

    of 219 teams, public leaderboard 4.090

    Open

3 of 5

Contact

Abstract illustration of a direct contact link
Connect on LinkedIn